Empreu aquest identificador per citar o enllaçar aquest ítem: http://hdl.handle.net/10609/146755
Títol: Preserved central nervous system functioning after use of romidepsin as a latency-reversing agent in an HIV cure strategy
Autoria: Muñoz Moreno, Jose Antonio
Carrillo Molina, Sara
Martínez Zalacaín, Ignacio
Miranda, Cristina
Manzardo, Christian
Coll, Pep  
Meulbroek, Michael  
Hanke, Thomas  
Garolera, Maite  
Miró, Josep M.
Brander, Christian  
Clotet Sala, Bonaventura  
Soriano-Mas, Carles  
Molto, Jose  
Mothe, Beatriz  
BCN02-Neuro Substudy Group
Altres: Fundació Lluita Contra la SIDA i les Malalties Infeccioses (FLS)
Hospital Universitari Germans Trias i Pujol
Universitat Oberta de Catalunya. Estudis de Psicologia i Ciències de l'Educació
Institut d'Investigació Biomèdica de Bellvitge
Universitat de Barcelona (UB)
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Projecte dels NOMS-Hispanosida
Institut de Recerca de la Sida (IrsiCaixa)
University of Oxford
Kumamoto Daigaku
Consorci Sanitari de Terrassa
Universitat de Vic-Universitat Central de Catalunya (UVic-UCC)
Institució Catalana de Recerca i Estudis Avançats (ICREA)
Instituto de Salud Carlos III
Universitat Autònoma de Barcelona (UAB)
Citació: Muñoz-Moreno, J.A., Carrillo-Molina, S., Martínez-Zalacaín, I., Miranda, C., Manzardo, C., Coll, P., Meulbroek, M., Hanke, T., Garolera, M., Miró, J.M., Brander, C., Clotet, B., Soriano-Mas, C., Moltó, J. & Mothe, B. (2022). Preserved central nervous system functioning after use of romidepsin as a latency-reversing agent in an HIV cure strategy. AIDS, 36(3), 363-372. doi: 10.1097/QAD.0000000000003121
Resum: Objective: To assess the central nervous system (CNS) impact of a kick&kill HIV cure strategy using therapeutic vaccine MVA.HIVconsv and the histone deacetylase inhibitor (HDACi) romidepsin (RMD) as latency-reversing agent. Design: Neurological observational substudy of the BCN02 trial (NCT02616874), a proof-of-concept, open-label, single-arm, phase I clinical trial testing the safety and immunogenicity of the MVA.HIVconsv vaccine and RMD in early-treated HIV-1-infected individuals. A monitored antiretroviral pause (MAP) was performed, with cART resumption after 2 pVL more than 2000 copies/ml. Reinitiated participants were followed for 24 weeks. Methods: Substudy participation was offered to all BCN02 participants (N = 15). Evaluations covered cognitive, functional, and brain imaging outcomes, performed before RMD administration (pre-RMD), after three RMD infusions (post-RMD), and at the end of the study (EoS). A group of early-treated HIV-1-infected individuals with matched clinical characteristics was additionally recruited (n = 10). Primary endpoint was change in a global cognitive score (NPZ-6). Results: Eleven participants from BCN02 trial were enrolled. No significant changes were observed in cognitive, functional, or brain imaging outcomes from pre-RMD to post-RMD. No relevant alterations were detected from pre-RMD to EoS either. Scores at EoS were similar in participants off cART for 32 weeks (n = 3) and those who resumed therapy for 24 weeks (n = 7). Controls showed comparable punctuations in NPZ-6 across all timepoints. Conclusion: No detrimental effects on cognitive status, functional outcomes, or brain imaging parameters were observed after using the HDACi RMD as latency-reversing agent with the MVA.HIVconsv vaccine in early-treated HIV-1-infected individuals. CNS safety was also confirmed after completion of the MAP.
Paraules clau: sistema nerviós central
inhibidors de la histona deacetilasa
infecció pel VIH
estratègies kick&kill
MVA.HIVconsv
romidepsina
DOI: http://doi.org/10.1097/QAD.0000000000003121
Tipus de document: info:eu-repo/semantics/article
Versió del document: info:eu-repo/semantics/acceptedVersion
Data de publicació: 1-mar-2022
Llicència de publicació: https://creativecommons.org/licenses/by-nd/4.0  
NO
Apareix a les col·leccions:Articles
Articles cientÍfics

Arxius per aquest ítem:
Arxiu Descripció MidaFormat 
muñoz_aids_preserved.pdf343,72 kBAdobe PDFThumbnail
Veure/Obrir
Comparteix:
Exporta:
Consulta les estadístiques

Els ítems del Repositori es troben protegits per copyright, amb tots els drets reservats, sempre i quan no s’indiqui el contrari.